Medical Device Competition Heats Up In China
This article was originally published in PharmAsia News
Executive Summary
In order to grab a share of China's huge potential medical devices business, multinational medical device manufacturers are establishing foothold in the medium- and low-end market through collaborations or mergers. In the patient monitoring sector, market share of MNCs has declined from a high of 70 percent to the current 30 percent due to lower-priced local brands such as Shenzhen Mindray and Goldway. To consolidate its leading position in China, Philips recently made its first acquisition by buying Goldway Industrial. Industry analysts observe that the acquisition will heat up the competition if Philips puts its brand on Goldway-made products without raising prices. To address the possible adverse impact, Mindray has begun shifting its focus to the high-end market to build up its international competitive advantage. (Click here for more - Chinese Language)
You may also be interested in...
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.